IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden spoke with Proactive's Stephen Gunnion about the company’s £2.7 million Phase 3 Huntington’s disease clinical trial contract, its second win in the field in 12 months, and growing opportunities in neuroscience drug development. Goorden explained that large, long-running Phase 3 trials provide greater revenue visibility and scope to improve gross margins through IXICO’s imaging and data analysis services. He highlighted the momentum in Huntington’s research, with 44 ongoing interventional trials, alongside 192 in Alzheimer’s disease, describing neuroscience as a sector experiencing a renaissance. The discussion also covered precision medicine and the growing role of artificial intelligence in clinical trials. Goorden outlined how IXICO is automating and standardising its technology platform to help identify the right patients for the right treatments. He said the company is growing ahead of the imaging clinical trials market, supported by investment in its technology, and discussed how further advances in AI could create new opportunities for the business. Visit Proactive's YouTube channel for more company interviews, healthcare technology updates and investment news. Give this video a like, subscribe to the channel and enable notifications for future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #IXICO #IXICOplc #HuntingtonsDisease #ClinicalTrials #Phase3Trials #Neuroscience #MedicalImaging #PrecisionMedicine #ArtificialIntelligence #AIDrugDevelopment #Biotechnology #HealthcareTechnology #AlzheimersResearch #ProactiveInvestors